Literature DB >> 18480381

Characterization of obestatin in rat and human stomach and plasma, and its lack of acute effect on feeding behavior in rodents.

Muhtashan S Mondal1, Koji Toshinai, Hiroaki Ueno, Keiichi Koshinaka, Masamitsu Nakazato.   

Abstract

Obestatin is a 23-amino acid peptide, initially isolated from rat stomach as an endogenous ligand for the orphan G-protein-coupled receptor. Obestatin is derived from proteolytic cleavage of a 117-amino acid precursor, preproghrelin. Ghrelin increases food intake, body weight, and gastric emptying, whereas obestatin has the opposite effects. In this study, we characterized obestatin in both rat and human stomach, and investigated the peptide's effect on feeding behavior. Using reversed-phase high-performance liquid chromatography coupled with RIAs specific for rat and human obestatin, we detected a very small amount of obestatin, compared with ghrelin, in the gastric fundi. The ratios of obestatin to ghrelin are 0.0039 and 1.94% respectively in the rat and human gastric fundi. In humans, plasma obestatin accounted for 5.21% of the ghrelin concentration, whereas it was undetectable in rat plasma. Plasma ghrelin concentration decreased after a meal in normal subjects, whereas obestatin concentration did not change. When administered centrally or peripherally, obestatin did not suppress food intake in either free-feeding or fasted rodents. Administration of obestatin did not antagonize ghrelin-induced feeding. These findings indicate that obestatin is present at very low levels compared with ghrelin in both rat and human, and has no acute effect on feeding behavior.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480381     DOI: 10.1677/JOE-08-0082

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

Review 1.  Interaction between gastric and upper small intestinal hormones in the regulation of hunger and satiety: ghrelin and cholecystokinin take the central stage.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Curr Protein Pept Sci       Date:  2011-06       Impact factor: 3.272

Review 2.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

Review 3.  Role of the Ghrelin System in Colorectal Cancer.

Authors:  Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

Review 4.  Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight.

Authors:  Andreas Stengel; Miriam Goebel; Lixin Wang; Yvette Taché
Journal:  Peptides       Date:  2009-11-26       Impact factor: 3.750

Review 5.  Ghrelin and eating disorders.

Authors:  Deniz Atalayer; Charlisa Gibson; Alexandra Konopacka; Allan Geliebter
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-30       Impact factor: 5.067

6.  Yin and Yang - the Gastric X/A-like Cell as Possible Dual Regulator of Food Intake.

Authors:  Andreas Stengel; Yvette Taché
Journal:  J Neurogastroenterol Motil       Date:  2012-04-09       Impact factor: 4.924

7.  Combination of Selective Immunoassays and Mass Spectrometry to Characterize Preproghrelin-Derived Peptides in Mouse Tissues.

Authors:  Rim Hassouna; Dominique Grouselle; Giovanni Chiappetta; Joanna Lipecka; Oriane Fiquet; Catherine Tomasetto; Joëlle Vinh; Jacques Epelbaum; Virginie Tolle
Journal:  Front Neurosci       Date:  2017-04-20       Impact factor: 4.677

Review 8.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

9.  Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms.

Authors:  Manuela Aragno; Raffaella Mastrocola; Corrado Ghé; Elisa Arnoletti; Eleonora Bassino; Giuseppe Alloatti; Giampiero Muccioli
Journal:  Cardiovasc Diabetol       Date:  2012-10-15       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.